Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
November 4, 2025
Earnings Call Speaker Segments
Melissa Drell
executiveThanks, Operator. Good day, everyone, and thanks for being with us on today's Heron Therapeutics earnings call, where we'll go over the company's financial results for the quarter that closed on September 30, 2025. Joining me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy, and Engagement. If you're on the conference call, slides are available through the webcast, and you can also find them on the Investor Relations page of our website once today's call wraps up. Before we get started, a quick reminder that during this conference call, the company will be making forward-looking statements. Please note that anything we say that isn't a statement of historical fact counts as a forward-looking statement. That covers remarks regarding the company's projections, expectations, plans, beliefs, and future performance, and all of these are forward-looking statements under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Such statements rest on judgment and analysis as of the date of this conference call, and they carry numerous important risks and uncertainties that might cause actual results to differ materially from what those forward-looking statements describe. The risks and uncertainties tied to the forward-looking statements made during this conference call and webcast are laid out in the Safe Harbor statement in today's press release as well as in Heron's public periodic filings with the Securities and Exchange Commission. Unless the law requires otherwise, Heron takes on no obligation to update these forward-looking statements to reflect future events or actual outcomes, and it does not intend to do so. I'd now like to hand the call over to Craig Collard, Chief Executive Officer of Heron.
Craig Collard
executiveThank you, Melissa. Greetings, everyone, and you're all welcome to Heron Therapeutics' earnings call for the third quarter of 2025. We're excited today to walk you through our Q3 results and to give you a sense of where product sales stand. Let me start with a few of the quarter's most important wins. Finishing our financing successfully stood out as a major achievement. Since the day I came on board, this has weighed on the company, and we're happy it's now resolved. Now that this matter is settled, the management team is free to concentrate entirely on commercial execution and growing our products. Alongside that financing milestone, Team Heron turned in robust operational and financial results during Q3. Net revenues came to $38.2 million for the quarter, and $114.3 million for the year to date. That translated into Adjusted EBITDA of $1.5 million in the quarter and $9.5 million year to date. Gross margin stood at 68.8%, a bit lower than in prior quarters, largely because of a one-time write-off tied to Sustol polymer inventory. Over the last several months, Sustol has been declining as competition in the market has grown, and we anticipate that pattern will persist into the foreseeable future. CINVANTI, by contrast, keeps surpassing what we expected. Throughout this year we've kept a cautious view, expecting CINVANTI might slip somewhat as we entered Q3 and Q4. That slippage hasn't shown up yet. Even with the competitive pressure that has long weighed on our average selling price, we're happy to see net sales holding reasonably steady, and we think this favorable pattern will carry through Q4 and into next year. Now for our acute care portfolio: during Q3 we put several new programs in place, among them CrossLink Ignite, an incentive-driven effort to boost distributor engagement; the rollout of the 200 mg Vial Access Needle, or VAN; and the formation of the IBM team, a dedicated sales group concentrating solely on APONVIE. Each of these rolled out at a different point in the quarter and they're starting to make a real difference. That's the reason we've said all along that we expect the acute products to inflect more noticeably as we progress through late Q3 and Q4 of 2025. ZYNRELEF net sales rose 49% in Q3 2025 versus Q3 2024, while APONVIE net sales climbed 173% over that same span. Even more significant, genuine momentum in acute care is finally showing up. Quarterly net revenues and unit demand were healthy, but weekly unit demand from late September through October has reached the highest level we've ever recorded, a clear signal of a possible trend break. Mark will go into further detail on that during his prepared remarks. Finally, our J-code for ZYNRELEF took effect on October 1. That's a big win for Heron and for the providers who depend on ZYNRELEF in their practices. The J-code will simplify reimbursement and cut administrative burden, particularly as the NOPAIN Act keeps building momentum. We think this adjustment is going to make it easier for patients to get coverage and access under both government and commercial payers, which should in turn help drive wider adoption and improved outcomes for patients; beyond that, our pre-filled syringe effort keeps moving forward, with a path toward a potential approval in late 2027. Any questions about PFS or other development programs will be handled by Bill Forbes, our Head of Development, during the Q&A. For Heron, this quarter was a busy one and a successful one as well. Given rising demand for ZYNRELEF, APONVIE, and even SUSTOL, we couldn't be more excited about where the business is headed from here. At this point I want to hand the call over to Mark Hensley, our Chief Operating Officer. Please go ahead, Mark.
Mark Hensley
executiveAppreciate that, Craig. Within acute care, ZYNRELEF carried its momentum through Q3. Adoption here happens one site at a time, one case at a time. Getting access opens the door, OR proof drives conversion, and protocols lock it in; our attention went to clearing friction and sharpening execution. The VAN simplified OR prep. With the Ignite program, distributors stayed concentrated on accounts we can win. Standardizing technique and backing protocol uptake came from our education and medical support teams. Since October 1, ZYNRELEF holds a permanent product-specific J-code, which makes billing discussions clearer. Zooming out, friction removal and focus are the core theme. Both APONVIE and CINVANTI benefited from those same disciplines. Over in oncology supportive care, CINVANTI stays a dependable anchor. As APONVIE grows and deepens our ties with anesthesia and pharmacy, CINVANTI ordering climbs in those hospitals. Let me walk you through how that progress appears in the revenue figures on slide six. Net sales for our acute care franchise hit $12.3 million in the third quarter, rising from $10.7 million in the second quarter. ZYNRELEF net sales came to $9.3 million. Versus $6.2 million in last year's third quarter, that is 49% growth year over year, and it is up from $8.2 million in the second quarter. The drivers stay consistent: the VAN, the Ignite program steering distributors toward winnable accounts, backing from our education and medical support teams, and now the clarity of a permanent J-code. APONVIE net sales reached $3 million; versus $1.1 million last year, that is 173% growth year over year, and up from $2.5 million in the second quarter. Third quarter APONVIE growth happened before the dedicated team was at full strength. Training wrapped in October and the team hit the field in early Q4 to sustain momentum; now let me show how that demand appears in ZYNRELEF operating metrics on slide seven. Our installed base keeps growing as sites progress from a first case to protocolized use. Average daily units went from 882 in last year's third quarter to 1,127 in this year's third quarter, roughly a 28% increase. Ordering accounts climbed from 705 to 833 across that same span; credit goes to friction removal and focus: the VAN, Ignite program, our education and support teams, and permanent J-code clarity smoothing reimbursement. You will also notice October plotted on the line, well above September. It is a preliminary single month, not a proxy for the fourth quarter. We will remain disciplined and let the quarter unfold. With that context, let's move to slide eight and APONVIE. APONVIE's trajectory looks strong. Demand units grew 142% year over year. Average daily units rose from 418 to 998. Ordering accounts went up from 299 to 405. We launched the dedicated APONVIE team on July 1. Six representatives concentrated on high-potential hospitals. Full training wrapped in October, so Q3 reflects partial deployment. Full activation supports momentum ahead. Additionally, publication of the 2025 PONV Prophylaxis Consensus Guidelines is expected in Q4. We expect APONVIE to be included in the guidelines, and that inclusion ought to drive a much greater level of awareness regarding both its availability and how it performs clinically. We're eager to line up our educational efforts and get the word out alongside the field sales and medical teams we've just grown. Moving on now to the oncology care franchise, which is on slide nine. Net sales for the oncology franchise came to $25.9 million during the third quarter. CINVANTI brought in roughly $24 million in net sales, which is a rise of around 6% compared with the same period a year ago and level on a sequential basis. As APONVIE widens its relationships across anesthesia and pharmacy, we're starting to observe CINVANTI pulling through within those very same institutions. SUSTOL net sales reached $1.9 million, a decline of roughly 32% versus the prior-year period. Our plan is to wind down commercialization across the coming 12 months as we assess possible product updates, with a potential reintroduction in late 2027 that would depend on development and regulatory headway. We'll keep supporting customers and handle this transition in a responsible manner. To close things out, we're witnessing structural progress. The VAN, the Ignite program, clinical education, and clarity on the permanent J-code are converting ZYNRELEF first cases into lasting protocols. APONVIE's hospital trajectory keeps getting stronger, backed by a team that's fully trained and strategically aligned, and that team is positioned ahead of the upcoming release of the updated 2025 PONV Prophylaxis Consensus Guidelines. CINVANTI stays a steady anchor, and we think that as APONVIE grows its hospital relationships, CINVANTI will stand to gain. October picked up for ZYNRELEF, though that's just a preliminary single month. We'll remain disciplined and allow the quarter to unfold. Thank you, and I'll hand things over now to Ira.
Ira Duarte
executiveAppreciate that, Mark. Product gross profit for the quarter that closed on September 30, 2025, came in at $26.3 million, or 68.8%, down from 71.2% during the matching stretch in 2024. Driving that decline were $1.4 million more in inventory reserves and write-offs that were recorded, plus a $1.3 million rise in the cost of units sold, largely tied to supplier mix. When we look at the nine months that ended September 30th, 2025, product gross profit reached $84.1 million, or 73.6%, up from 72.5% during the matching stretch in 2024. That gain reflects more units sold along with a lower cost per unit stemming from the supplier mix. SG&A expenses for the quarter that closed September 30th, 2025, totaled $26.9 million, versus $23.3 million during the matching stretch in 2024. The main driver of that increase was higher personnel and related expenses from new hires, together with increased ZYNRELEF marketing costs. SG&A expenses for the nine months that ended September 30, 2025, came to $78 million, versus $77.3 million during the matching stretch in 2024. That rise is mostly attributable to increased marketing costs related to ZYNRELEF, offset by a decrease in personnel and related costs from terminations and a one-time stock compensation expense in 2024 that did not reoccur in 2025, along with a decrease in legal expenses from timing of litigation. Research and development expenses came to $3.5 million for the quarter that closed September 30, 2025, versus $4.5 million in the comparable 2024 period. That decrease is mostly attributable to timing of expenses. Research and development expenses came to $8.7 million for the nine months that ended September 30, 2025, versus $13.5 million in the comparable 2024 period. That decrease stems from lower personnel and related expenses from terminations and fewer write-offs of property and equipment and other assets; for the quarter that closed September 30th, 2025, we recorded a net loss of $17.5 million, versus a net loss of $4.8 million during the matching stretch in 2024. The bigger net loss is mostly attributable to the $11.3 million loss on debt extinguishment recognized in the quarter; for the nine months that ended September 30th, 2025, and 2024, we recorded a net loss of $17.2 million. The net loss for the nine months that ended September 30, 2025, included a one-time charge of $11.3 million tied to our recent debt extinguishment. Cash and short-term investments at September 30th, 2025, stood at $55.5 million. Thanks to the debt and equity transactions completed in the quarter that closed September 30th, 2025, $13.1 million was added to cash and short-term investments. Had we left out depreciation, stock-based compensation, along with inventory reserves and write-offs, our Adjusted EBITDA results would have shown positive operating income of $1.5 million for the three months ended September 30, 2025, versus a loss of $400,000 during the same period in 2024; when it comes to the nine months ended September 30, 2025, our Adjusted EBITDA stands at $9.5 million operating income, compared with a loss of $700,000 for the same period in 2024. Our previously given guidance for net revenue of $153 million-$163 million and Adjusted EBITDA of $9 million-$30 million is being reaffirmed. At this point, we'd like to open the call for any questions.
Carl Byrnes
analystAppreciate taking the question, and congratulations on the quarter. Going back to that slide about ZYNRELEF and how the first few weeks of October looked — it seems like you're approaching 18% growth. That's measured month over month, right?
Mark Hensley
executiveThat's right, Carl, yes. More or less accurate. Yeah, somewhere in the 17%-18% range.
Carl Byrnes
analystGreat, that's fantastic. Now I have a question about the finances. When we examine gross profit margin and remove that one-time stocking charge — I believe it's roughly $2.2 million — what remains is an adjusted gross profit margin of about 74.5%. Is that right?
Ira Duarte
executiveYes, Carl, that's right.
Mark Hensley
executiveYes, that is correct.
Ira Duarte
executiveThat matches where we've stood over the past several quarters.
Carl Byrnes
analystAll right, and then there's another adjustment—the debt extinguishment. If we back that out, what would net interest income be? Should we figure it around $2.1 million, or is there a different figure we ought to apply?
Ira Duarte
executiveLooking ahead, yes, roughly $2.5 million is what it would likely be.
Carl Byrnes
analystAll right, so 2.1 for this quarter, though in a way that's adjusted across the entire quarter.
Ira Duarte
executiveAcross the entire quarter, that's right.
Carl Byrnes
analyst2.5 and up. That's right. Great. Excellent. Well done once more. Appreciate it.
Mark Hensley
executiveThank you, Carl.
Brandon Folkes
analystHello, and thank you for allowing me to ask my questions. Congratulations on the quarter. Perhaps, from my end, since it's still very early days for the internal sales team, could you discuss how you're currently evaluating those teams on ZYNRELEF and APONVIE? Also, how are you considering possibly expanding them in 2026, or what measure of success would trigger such expansion in 2026, and then what further commercial-side investments might you be contemplating behind both products in 2026?
Mark Hensley
executiveThanks for asking, Brandon. Mark Hensley here. I'll begin, and then we'll have Craig wrap it up. On the internal side, we're quite happy with the structural changes implemented at the start of Q3. As a reminder, there is now a dedicated team for ZYNRELEF and another dedicated team for APONVIE. That APONVIE team has also started doing some work with CINVANTI. We believe there's substantial synergy on both sides there. The greater focus, in our view, has partly driven the results we're seeing this quarter and certainly will as we move into next year. Beyond that, our alignment with distributor partners has improved; putting all of these elements together, we believe, will lead to higher sales going forward. Yeah, Brandon, I'd add to that as we consider the product or products moving ahead. We've consistently said that when we observe certain pockets around the country taking off — and we have what you'd call favorable circumstances, such as gaining access to an account, solid CrossLink participation, and definitely staff in that region — once that kind of success appears, we'd obviously want to replicate it wherever possible. Looking ahead, we keep seeking those pockets, and as the data indicates, we're starting to see them. We're currently working through our budgeting process for the year, and I think we'll examine where we can add in particular pockets while, again, remaining within profitability and so on. I believe you'll hear more about this soon because, once again, we're starting to notice a somewhat different trend. If we can broaden that, we'd certainly like to do so.
Brandon Folkes
analystGreat. I might have one more thing to ask, and it concerns ZYNRELEF. Of course, those demand curves appear genuinely, genuinely strong. Thanks for providing them. Since the VAN became available quite substantially during the quarter, was there any benefit from inventory stocking showing up in revenue, in the reported revenue figure for 3Q on ZYNRELEF?
Mark Hensley
executiveWe didn't observe that sort of comparable lift when we introduced the 400 VAN. Since the 200 VAN accounts for only roughly 35% of overall sales, there was a slight, shall we say, bump, I suppose, yet not at the level we experienced with the 400. Inventory stayed fairly steady relative to earlier quarters.
Brandon Folkes
analystThat's wonderful to hear. Congratulations on the quarter, and that's everything from my side.
Mark Hensley
executiveThank you. Appreciate it, Brandon.
Serge Belanger
analystHello, and good morning. My first question is about the NOPAIN Act. You've just provided an update on how it's being rolled out. What are you observing among commercial plans — are they mirroring what Medicare has done? Second, regarding the oncology care franchise, perhaps you could give us a bit more detail on your long-term view for that franchise. It sounds as though you anticipate Sustol will stay under pressure for the foreseeable future. As for CINVANTI, do you think competitive pressures will return even though the ones anticipated in the third or fourth quarter never showed up? Thanks.
Mark Hensley
executiveYes, Serge, I'll handle the CINVANTI question, and then I'll hand the NOPAIN Act one over to Kevin. As we've said throughout the year, including in my prepared remarks on CINVANTI, we believed that given the competition in the market, a slight decline might occur in Q3 and Q4; that hasn't happened yet. We've been quite steady in retaining accounts and so forth. As you noted, this is a highly competitive area, and pressure will persist. Occasionally we might lose an account, or we might have to lower our price to hold onto one. That's simply the nature of the market we operate in. We're going to keep viewing this rather conservatively. On the positive side, though, with the IBM team we have in place, we're starting to promote CINVANTI a little more through reps in hospital accounts. We believe that could have a beneficial effect. The same competition is still there, but because we now have a somewhat louder voice in the market, we actually secured an account roughly three weeks ago that was quite substantial. If we can continue doing that, we think we can keep things relatively steady going forward. We'll keep updating each quarter, but I believe our outlook stays pretty much in line with what we've stated previously.
Craig Collard
executiveOkay. Hi, Serge, this is Kevin Warner. About the NOPAIN Act and what we're seeing in the field, momentum is certainly beginning to build. Like we mentioned before, we expected it would require 6 to 9 months, with the back half of the year being when providers and systems became educated that reimbursement outside the bundle was possible. That isn't the norm, as we all know. Education is occurring across every segment, including from a few of our competitors — clearly, other businesses covered under the NOPAIN Act. They're up at podium sessions, such as at ASA, getting that message out. We keep spreading the word, putting the systems in place, and supplying educational resources on how to bill separately in practice. On commercial payers, regarding your question, we're also observing a bit of momentum. Our belief is they'd need time to reevaluate and take a backward look at it and see how implementation is going. You've got providers such as Aetna and Cigna offering separate reimbursement. It differs from state to state among the individual commercial plans we're seeing. Broadly, as an estimate, roughly 75% of all procedures indicated for ZYNRELEF, particularly our target procedures, have some type of coverage, whether that's a Medicare plan or a commercial one. There are a few other items from an economic standpoint that are tailwinds heading into 2025 for us when you consider the Teams model from CMS, which is a value-based care model. You're considering things such as patient-reported outcomes and satisfaction. Are you feeling pain? Do you have PONV? That will be a meaningful tailwind. Additionally, the inpatient-only list dissolving — about 285 orthopedic procedures specifically are being removed from that inpatient-only list. That will now make them outpatient-eligible procedures and therefore reimbursable under things such as the NOPAIN Act. A great deal of value and impact is reaching our patients and truly shifting the model toward value-based care, seeking these advances in our healthcare system, long-acting advances such as ZYNRELEF and APONVIE that can help enable this transition as we move through our phases of care.
Mark Hensley
executiveRight. Serge, to touch on the latter portion of what you asked about Sustol. It's a comparable situation to what we're dealing with for CINVANTI, though things have been somewhat more competitive in that area. Once again, our account count is lower. Over these past several years, what we've observed is a steady erosion, plus a steady erosion in our ASP. So we've made the call to wind this product down across the coming period, into next year. Once again, the intention is to explore whether we can enhance how that product is delivered, perhaps through a thinner gauge needle, or something along those lines. Our hope is to potentially launch that in late 2027, carrying into 2028, as a relaunched offering. Once again, there are levers available to us involving our selling price and similar matters that could potentially return this product to the market. We'll share more on that down the road, along with the ideas we have. As of now, the plan is to wind this down as we progress really toward the close of next year.
Carl Byrnes
analystGreat. Thanks.
Bill Forbes
executiveHi there, and thanks for asking about this. Speaking is Bill Forbes, and I'll share a brief status update. Our registration batches were just produced not long ago, which allowed us to kick off the stability testing effort. Every newly developed product, as you're aware, must go through a minimum of twelve months of real-time stability testing, and that process is now underway. Getting past this milestone feels good, and it explains the timing of what we're pursuing. Naturally, after the stability work wraps up, we'll move forward with the submission, and ideally it gains approval during 2027. Regarding the effect, I'd say that, based on what the VAN shows, we've seen somewhat of a rise. When it comes to making ZYNRELEF easier and faster to apply and use, I'd say the VAN represented a significant advance. With the Pre-filled syringe, we've moved up yet another level. In that situation, clearly, all we need to do is unseal the Pre-filled syringe's packaging and hand it over to the surgeon, who can then proceed with placing the product. As for what happens on the receiving end, I'd argue the simplification is even more dramatic. And I'm confident this will accelerate how quickly accounts shift over to using ZYNRELEF. I'm not sure whether Mark wants to add anything here.
Mark Hensley
executiveNo, I thought that was excellent. Yeah. The only thing I'd add is that I agree completely with Bill. If you consider ease of use, we still face a situation where, upon going in to onboard an account, some training is required, despite the fact that the VAN has made a dramatic improvement, along with the ability to pull the product from the vial. If you imagine truly streamlining your product so that now you walk in, open a tray, pour the product into the sterile field, and essentially it's good to go, that removes just one step from the process. Once again, we definitely believe this will deliver a favorable result. Once again, as progress continues, we feel this simply improves the product further and provides one more advantage. Okay. Thank you. I do have a follow-up. Regarding the J-code for ZYNRELEF, does it also apply to the pre-filled syringe as well as the VAN, correct? That would be once the Pre-filled syringe becomes available. Yes, that's right. Okay. Understood. Understood. Thank you.
Craig Collard
executiveAppreciate that, Ralph Ritter. Thanks to all of you for being with us on today's call, and we're looking forward to talking with everyone again next quarter.
Operator
operatorWe appreciate everyone joining us on this call. That brings the session to an end. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.